Research Topics
| Anjali GuptaSummaryAffiliation: University of Pennsylvania Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Radiation response in two HPV-infected head-and-neck cancer cell lines in comparison to a non-HPV-infected cell line and relationship to signaling through AKTAnjali K Gupta
Department of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA
Int J Radiat Oncol Biol Phys 74:928-33. 2009..We are in the process of starting a clinical trial in H&N cancer patients using nelfinavir (NFV) (which inhibits Akt) and it would be important to know the effect of HPV on radiation response +/- NFV...- Local recurrence in head and neck cancer: relationship to radiation resistance and signal transductionAnjali K Gupta
Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania 19104 6072, USA
Clin Cancer Res 8:885-92. 2002..We have shown previously that radioresistance could be conferred via the Ras-PI3K pathway. Here we investigate the contribution of EGFR to this pathway and its impact on treatment outcome... - Signaling pathways in NSCLC as a predictor of outcome and response to therapyAnjali K Gupta
Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
Lung 182:151-62. 2004..This further suggests that Akt might be a useful target for sensitization of NSCLC to radiation... - The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein responseAnjali K Gupta
Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
Neoplasia 9:271-8. 2007..These findings may have important implications in understanding how nelfinavir may increase radiation sensitivity and also result in downregulation of the PI3K/Akt pathway... - HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivoAnjali K Gupta
Department of Radiation and Biostatistics, University of Pennsylvania, Philadelphia 19104, USA
Cancer Res 65:8256-65. 2005..Because there is abundant safety data on HPIs accumulated in thousands of HIV patients over the last 5 years, these agents are excellent candidates to be tested as radiation sensitizers in clinical trials... - Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002Anjali K Gupta
Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
Int J Radiat Oncol Biol Phys 56:846-53. 2003..Inhibition of PI3K by LY294002 can synergistically enhance radiation efficacy. This acts as a proof of principle that inhibition of the Ras to PI3K pathway could be useful clinically... - C-Raf-1 protein kinase is not essential for Ras transformation of mouse embryo fibroblastsAnjali K Gupta
Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania 19104 6072, USA
Cancer Biol Ther 2:73-5. 2003..Both cell lines were however able to form tumors in nude mice. These results suggest that c-Raf-1 is not required for Ras transformation in this system... - Signaling inhibition with radiation in colorectal cancer: clinical trialsW Gillies McKenna
Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19004, USA
Semin Oncol 30:56-67. 2003..Identifying a common signal for EGFR, Ras, or PTEN that results in radiation resistance may uncover targets for developing molecular-based radiosensitization protocols for tumors resistant to radiation and thus improve local control... - Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapyNabendu Pore
Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
Cancer Res 66:9252-9. 2006..These data support the use of nelfinavir in combination with radiation in future clinical trials... - Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiationJohn P Plastaras
Laboratory of Molecular Oncology and Cell Cycle Regulation, Department of Medicine Hematology Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
Cancer Res 67:9443-54. 2007..This study establishes a foundation for clinical testing of sequential fractionated radiation followed by sorafenib in gastrointestinal and other malignancies... - EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanismsNabendu Pore
Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
Cancer Res 66:3197-204. 2006..Similar results were obtained with erlotinib in SQ20B and gefitinib in HSC3 squamous carcinoma cells. These results indicate that there are at least two separate mechanisms by which EGFR inhibitors decrease VEGF expression... - Signaling pathways in adenoid cystic cancers: implications for treatmentAnjali K Gupta
Department of Radiation Oncology, University of Iowa Hospital and Clinics, Iowa City, IA, USA
Cancer Biol Ther 8:1947-51. 2009..Both P-Akt and P-MAPK were inhibited with NFV in ACC3 cells and this resulted in growth inhibition and clonogenic death. In patients where re-irradiation or further surgery is not an option, a trial of NFV may be warranted... - Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavirZibin Jiang
Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
Cancer Res 67:4467-73. 2007..These results support the clinical investigation of nelfinavir in combination with radiation and temozolomide in future clinical trials for patients with glioblastomas... - The RAS signal transduction pathway and its role in radiation sensitivityW Gillies McKenna
Departments of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19103, USA
Oncogene 22:5866-75. 2003..Identifying a common signal for EGFR, RAS, or PTEN that results in radiation resistance may uncover targets for developing molecular-based radiosensitization protocols for tumors resistant to radiation and thus improve local control... - Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humansJohn P Plastaras
Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
Cancer Biol Ther 7:628-35. 2008.... - HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cellsNabendu Pore
Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Neoplasia 8:889-95. 2006..Our results support further research into these protease inhibitors for use in future clinical trials for patients with glioblastoma multiformes... - Bortezomib sensitizes human head and neck carcinoma cells SQ20B to radiationCharles N Weber
Department of Radiation Oncology, University of Pennsylvania, 3620 Hamilton Walk, Philadelphia, PA 19104, USA
Cancer Biol Ther 6:156-9. 2007..The dose of bortezomib is also 2 logs less as a sensitizer than that required for single agent efficacy. Further studies should be done to explore this model in vivo... - Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiationGary D Kao
Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
J Biol Chem 282:21206-12. 2007..These results together support a direct link between Akt activation, repair of DNA damage, and radioresistance in glioblastoma. Targeting the PI3K/Akt pathway may modulate DNA repair to improve the efficacy of radiation therapy... - Farnesyltransferase inhibitors as radiation sensitizersW Gillies McKenna
Department of Radiation Oncology, University of Pennsylvania, Philadelphia 19104, USA
Semin Radiat Oncol 12:27-32. 2002..Additional clinical trials should shed light on the potential of this and other farnesyltransferase inhibitors to serve as radiosensitizers and may identify molecular markers that could predict a response to these agents... - The influence of Ras pathway signaling on tumor radiosensitivityIn Ah Kim
Department of Radiation Oncology, 185 John Morgan Bldg, 37th and Hamilton Walk, University of Pennsylvania, Philadelphia, PA 19104-6072
Cancer Metastasis Rev 23:227-36. 2004..We will also point out new means of studying the contribution of Ras and Ras pathway components that could contribute to defining new targets for inhibition in the context of radiation therapy... - A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancerNeil E Martin
Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
Clin Cancer Res 10:5447-54. 2004..CONCLUSIONS: The combination of L-778,123 and radiotherapy at dose level 1 showed acceptable toxicity in patients with locally advanced pancreatic cancer. Radiosensitization of a patient-derived pancreatic cancer cell line was observed... - Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigationsThomas B Brunner
Department of Radiation Oncology, University of Pennsylvania, Philadelphia 19104-6072, USA
Cancer Res 63:5656-68. 2003..We conclude that the rational combination of FTIs with other therapies, taking into account the biological activities of the individual agents, may improve the clinical results obtained with FTIs...
Research Grants
- Radiosensitization with the HIV protease inhibior Nelfinavir in NSCLCAnjali Gupta; Fiscal Year: 2007..Specific Aim 3. To investigate in vitro the molecular mechanisms by which NFV results in sensitization. ..